ClinicalTrials.gg
Active, not recruitingNCT07939360Updated Nov 16, 2026

Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction.

An interventional study of low-level light therapy in Dry Eye and Dry Eyes Chronic, sponsored by Essilor International. Active, not recruiting at 7 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Essilor International · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2026, registered Oct 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Planned enrollment
147th of 473
144 · median 60
Started
2026
with 35 others
No phase
136 of 544
10 open now
Primary completion
2026-12
later than 24 of 62 live
Registered
539th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 147th largest by planned enrollment of the 473 interventional ones that give a count, is one of 36 that started in 2026, is one of 136 with no phase, reaches primary completion later than 24 of the 62 other live ones, and was the 539th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the non-inferiority of the Equinox System with respect to iLux 2020.

Approximately 120 participants are expected to take part in the research trial at a minimum of three (3) and up to five (5) sites across the United States.

The expected duration of the study will be six (6) months, and subject participation will take approximately four (4) weeks, including three (4) visits; pretreatment visit, Treatment Day, two (2) week follow-up and four (4) week follow-up visits.

The investigational therapy in this study is the use of low-level light therapy (LLLT) for the treatment of evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.

Low-Level Light Therapy (LLLT) is a treatment that uses gentle light to help patient cells work better. The light is applied to the skin using special devices. This light can help repair cells that are damaged and improve the function of healthy cells. It may also warm the natural oils in patient eyelids and could reduce tiny mites that sometimes live near the eyelashes. These effects may support overall eye health and comfort.

Participants will be randomized to receive treatment using the Equinox System (red mask) or iLux 2020 System ("iLux system"). There is a 50% chance participant will receive treatment with the Equinox System (red mask) and 50% chance participant will receive treatment with the iLux 2020 System.

For treatment, participant will be placed in either the prone or supine position. Participant will then wear the red mask for 17 minutes. Special protective eyewear or eye protection is not indicated for this treatment; participant will be instructed to keep eyes closed to ensure full application of the treatment to the upper and lower lids and the periorbital area. Immediately after the treatment is finished, the mask will be removed and the meibomian glands will be manually expressed by a trained and qualified clinician.

03

Conditions studied

  • Dry Eye
  • Dry Eyes Chronic

Keywords

  • Dry Eyes
  • Meibomian Gland Dysfunction
  • ophtalmologist
  • low-level light therapy
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female and male subjects aged ≥ 21 years
  2. Subject has a clinical diagnosis of evaporative dry eye disease (DED) due to MGD, confirmed by standardized MGS assessment in accordance with TFOS DEWS II and III guidelines (Positive diagnosis of DED \& MGD) . i. MG plugging score ≥2 (range 0-3) (3, 4) ii. Documented MG obstruction, defined as a total Meibomian Gland Score (MGS) of ≤ 12 in the lower eyelid of each eye based on assessment of 15 lower eyelid glands (maximum score 45)
  3. Subject has moderate to severe dry eye symptoms, as demonstrated by a baseline Ocular Surface Disease Index (OSDI-12) score consistent with moderate-severe disease severity (6, 7)
  4. Subject has evidence of MGS between 1 and 3 on Pult scale in both eyes
  5. Subject has TBUT \<10 seconds (TBUT retained as a diagnostic requirement to confirm tear film instability consistent with MGD but is not used for eligibility logic with OSDI)
  6. Subject agrees to and can comply with required medication wash-out: no dry-eye/MGD medications for 3 days prior to treatment and at least 2 weeks from the treatment day with no changes during the investigation (ocular lubricants allowed if regimen is stable)
  7. Subject is willing to maintain stable concomitant systemic medication regimens during the investigation unless medically required changes occur.
  8. Subject is willing and able to provide written or electronic informed consent (eIC)
  9. Subject is willing, able, and agrees to comply with all investigation requirements, including attending all visits/encounters and completing the patient-reported outcome (PRO) measurements
  10. Subject has no anticipated ocular procedures planned during the investigation period
  11. Subject is able to understand the study requirements, follow study procedures, and comply with all protocol-specified visits and assessments, in the opinion of the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Subject has any history of lid surgery
  2. Subject has a history of ocular or corneal surgery including intraocular, oculo-plastic, corneal or refractive surgery within one year prior to the screening visit.
  3. Subject has a punctal plug(s) or who has had punctal cautery
  4. Subject has experienced ocular injury, trauma, chemical burns, or limbal stem cell deficiency
  5. Subject has any history of ocular herpes simplex virus (HSV) or herpes zoster virus (HZV) infection of the eye or eyelid.
  6. Subject has a cicatricial lid margin disease identified via slit lamp examination, including pemphigoid, symblepharon.
  7. Subject has an active ocular infection
  8. Subject has active ocular inflammation at screening, or a history of chronic, recurrent ocular inflammation with an episode occurring within 3 months prior to screening
  9. Subject has an ocular surface abnormality that may compromise corneal integrity
  10. Subject has severe eyelid malpositions or structural abnormalities including entropion, ectropion, lagophthalmos, severe trichiasis, severe ptosis, floppy eyelid syndrome, blepharospasm, tumors, edema, or any configuration affecting lid function
  11. Subject has eyelid tattoos/permanent eyeliner
  12. Subject has artificial eyelash extensions or adhesive materials that may interfere with mask fit, heat delivery, or eyelid assessment and cannot be removed prior to treatment
  13. Subject has anterior blepharitis (staphylococcal, demodex or seborrheic grade 3 or 4 as per Dews II)
  14. Subject has changed the dosing of systemic medications or non-dry-eye/MGD ophthalmic medications within 30 days prior to screening
  15. Subject wears contact lens who is unwilling or unable to discontinue contact lens wear throughout the study (as specified)
  16. Subjects with known photosensitive disorders (e.g., lupus erythematosus, photosensitive eczema, albinism, light-induced headaches, or other conditions associated with light sensitivity).
  17. Subject is using any photosensitizing treatment such as tetracyclin or isotretinoin (Accutane) within 1 year prior to screening.
  18. Subject is using or has used cyclosporine-A 0.05%, lifitegrast 5%, or other prescription dry-eye immunomodulatory therapy within 3 months prior to screening.
  19. Subject is using or has used dry eye or MGD medications within 2 weeks prior to treatment (ocular lubricants allowed only if stable)
  20. Subject has performed warm compresses within 3 days prior to treatment and is unwilling to discontinue for the duration of the study
  21. Subject has used another ophthalmic device or agent within 30 days prior to screening.
  22. Any office-based dry eye treatment (e.g. IPL, thermal pulsation [Lipiflow], etc.) within 12 months prior to enrollment. In addition, Blephex or debridement within 3 months prior to enrollment is an exclusion.
  23. Meibomian gland expression within 6 months prior to enrollment. In addition, any history of meibomian gland probing is an exclusion
  24. Subject with known flouresceine allergy
  25. Subject is pregnant, nursing, or planning to become pregnant; pregnancy status will be determined by urine pregnancy testing at pre-treatment/baseline for women of
  26. Subject has any condition or systemic disease that, in the opinion of the investigator, may interfere with investigation participation or outcomes.
  27. Subjects showing any for the use of the predicate device
  28. Any retinal condition or abnormality that, in the opinion of the investigator, may interfere with the reliable assessment of potential retinal safety events or limit the interpretation of study-related findings.
  29. Subjects employed by EssilorLuxottica
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Active comparator
    iLux2

    Device: low-level light therapy

  • Experimental
    Equinox mask

    Device: low-level light therapy

Interventions

  • Devicelow-level light therapy

    Equinox mask used to deliver low-level light therapy

06

What researchers measure

Primary outcomes

  1. Equinox System not-inferiority to iLux® System with the respect of change from baseline to Week 4 in Meibomian Gland Score (MGS)

    Mean difference between Equinox System or iLux® System in Meibomian Gland Score (MGS) change from baseline to Week 4.

    Time frame: 4 weeks

  2. Equinox System not-inferiority to iLux® System with the respect of change from baseline to Week 4 in Tear Break-Up Time (TBUT)

    Mean difference between Equinox System and iLux® System in TBUT changes from baseline to Week 4

    Time frame: 4 weeks

Secondary outcomes

  1. Characterize the clinical performance of the Equinox System relative to the iLux® System with respect to patient-reported symptom) improvement (OSDI-12)

    Change from baseline to Week 4 in Ocular Surface Disease Index (OSDI-12) total score,

    Time frame: week 4

  2. Characterize the clinical performance of the Equinox System relative to the iLux® System with respect to patient-reported symptom) improvement tear meniscus height (TMH)

    Mean difference between the Equinox System and iLux® System in TMH score changes from baseline to Week 4.

    Time frame: week 4

  3. characterize the clinical performance of the Equinox System relative to the iLux® System with respect to patient-reported symptom) improvement lipid layer thickness (LLT)

    Mean difference between Equinox System or iLux® System in LLT score changes from baseline to Week 4

    Time frame: week 4

  4. characterize the clinical performance of the Equinox System relative to the iLux® System with respect to patient-reported symptom) improvement ocular redness

    Mean difference between Equinox System or iLux® System in Hyperemia score changes from baseline to Week 4

    Time frame: week 4

  5. characterize the clinical performance of the Equinox System relative to the iLux® System with respect to patient-reported symptom) improvement corneal integrity

    Mean difference between Equinox System or iLux® System in Corneal epithelial defect score changes from baseline to Week 4

    Time frame: week 4

  6. characterize the clinical performance of the Equinox System relative to the iLux® System with respect to patient-reported symptom) improvement conjunctival epithelial integrity

    Mean difference between Equinox System or iLux® System in Conjunctival epithelial defect score changes from baseline to Week 4

    Time frame: week 4

  7. characterize the clinical performance of the Equinox System relative to the iLux® System with respect to patient-reported symptom) improvement pain and discomfort

    Mean difference between Equinox System or iLux® Systemin change from baseline to Week 4 in pain and discomfort scores assessed using the 0-10 Numerical Rating Scale (NRS) which may be administered as a self completed survey or verbally.

    Time frame: week 4

Other outcomes

  1. Safety of the Equinox System with that of the iLux® System through a comprehensive evaluation of device- and procedure related risks on ocular surface findings

    Incidence, severity, seriousness, and expectedness of device and procedure related adverse events on ocular area

    Time frame: 4 weeks

  2. Safety of the Equinox System with that of the iLux® System through a comprehensive evaluation of device and procedure related risks on retinal safety

    Incidence, severity, seriousness, and expectedness of device and procedure related adverse events on retina

    Time frame: 4 weeks

  3. Safety of the Equinox System with that of the iLux® System through a comprehensive evaluation of device and procedure related risks on patient comfort

    collection of pain score (0-10) pre and post treatment (Zero is equivalent to no pain and 10 the worst possible pain) )

    Time frame: 4 weeks

07

Study locations

7 sites
  • MRB Eye Consultants, LLC
    Scottsdale, Arizona 85254, United States
  • East West Eye Institute
    Torrance, California 90505, United States
  • Louisville Eye Center PLLC
    Louisville, Kentucky 40222, United States
  • NothEast Eye Research Associates
    Stoneham, Massachusetts 02180, United States
  • Southern College of Optometry
    Medina, Minnesota 55340, United States
  • Laser Defined Vision
    Greensboro, North Carolina 27401, United States
  • Southern College of Optometry
    Memphis, Tennessee 38104, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

Of 113 industry-sponsored interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's planned 6 months is below that.

Counting every sponsor, half of 312 studies reached it within 10 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2026
First posted
Nov 16, 2026
StartActual
Jun 12, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07939360
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Jun 12, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion